← Eichor
Study identifier: NCT07361445 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Agilis RF TSP Early Feasibility Study

Condition: Cardiac Arrythmias · Left Atrial Appendage Closure  ·  Sponsor: Abbott Medical Devices

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is a prospective, acute, first-in-human, early feasibility study intended to assess the initial safety and performance of the Agilis™ Radiofrequency (RF) Transseptal (TSP) System in crossing the atrial septum for left atrial and left ventricular access during cardiac electrophysiology (EP) and interventional cardiology (IC) procedures. This study will be conducted in an acute setting. Subjects will be followed through hospital discharge, and no follow-up visits will be required for this study.

This description comes directly from the study's public registry record.

Talk to the study team

Ben Gansemer, PhD  ·  +1 952-715-2719  ·  benjamin.gansemer@abbott.com

Amber Miller, PhD  ·  612-413-7236  ·  amber.miller@abbott.com

Always discuss trial participation with your own doctor first.

Locations (3)

Arrhythmia Research Group (St. Bernards)Jonesboro, Arkansas, United StatesRecruiting
California Pacific Medical Center -Van Ness CampusSan Francisco, California, United StatesRecruiting
Research Medical CenterKansas City, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07361445